NUVISAN
The Science CRO

DRUG DISCOVERY

Antibody-drug conjugates

nuvisan.com

NUVISAN

Integrated solutions for antibody-drug conjugates

Nuvisan is your end-to-end partner for antibody-drug conjugate (ADC) development, from early-stage candidate assessment through to translational in vivo pharmacology.

We offer a fully integrated portfolio of ADC services, spanning conjugation chemistry, bioanalytical sciences, oncology and translational pharmacology.

Our multidisciplinary teams bring together extensive expertise to design solutions tailored to your specific program needs, helping ensure you receive actionable insights at every stage.

Whether you are exploring early-stage candidates or preparing for translational studies, we collaborate closely with you to accelerate data-driven decisions and de-risk your development path.

Our services include:

- ADC conjugation, purification and scale-up
- Drug-to-antibody ratio (DAR) characterisation and integrated bioanalytics
- ADC internalisation and mechanism-of-action studies
- In vivo translational pharmacology
- Biomarker profiling and indication selection.



THE SCIENCE CRO

Conjugation and bioanalytics

CONJUGATION AND CHARACTERISATION

Generating the right ADC candidate starts with the right conjugation strategy. We offer flexible, technology-agnostic conjugation workflows so you can explore multiple approaches and identify the candidate best suited to your program, including full purification and scale-up support.

- Multiple conjugation technologies available
- Cleavable and non-cleavable linker approaches
- Site-specific and stochastic conjugation workflows
- ADC purification and scale-up services

BIOANALYTICS AND DAR ANALYSIS

Our robust analytical workflows support the assessment of your ADC's quality and DAR determination, as well as translational pharmacokinetic (PK) studies and free payload characterisation. This helps you make informed go/no-go decisions before proceeding to in vivo studies.

- DAR determination using hydrophobic interaction chromatography (HIC), size-exclusion chromatography (SEC) and liquid chromatography-mass spectrometry (LC-MS)
- Analysis of antibody and total ADC (antibody conjugated with payload)
- Free payload quantification and stability assessment
- Endotoxin and aggregation analysis for in vivo studies



THE SCIENCE CRO

Biology and characterisation

ADC INTERNALISATION AND TRAFFICKING

Our high-content imaging platforms provide quantitative, reproducible data on binding, internalisation and intracellular trafficking, giving you a clear understanding of whether your ADC reaches its intracellular target and its potential efficacy.

- Quantification of ADC internalisation kinetics
- Co-localisation with lysosomes and endosomal markers
- High-throughput compatible workflows

CYTOTOXICITY AND MECHANISM-OF-ACTION

Demonstrating target-dependent cytotoxicity and understanding your ADC's mechanism-of-action are key milestones on the path to the clinic. Our integrated in vitro and in vivo assays help you characterise potency, confirm selectivity and assess bystander effects, giving you a clearer picture of your candidate's therapeutic potential.

- Dose-response characterisation
- Target expression versus ADC sensitivity analysis
- Bystander effect evaluation
- Internalisation-dependent potency confirmation



NUVISAN

In vivo pharmacology and translational profiling

IN VIVO PHARMACOLOGY

We support your ADC development with integrated oncology pharmacology studies to translate promising in vitro results into robust in vivo evidence. By combining an extensive in vivo model portfolio with translational PK/PD and biomarker workflows, we help you select the right model and generate translatable data to advance your candidate.

- Broad portfolio of >300 oncology models
- Xenograft, syngeneic and humanised mouse models
- Integrated PK/PD and exposure-response characterisation
- Imaging, ex vivo flow cytometry and tissue profiling

TRANSLATIONAL BIOMARKERS AND TISSUE PROFILING

Selecting the right indication and identifying the patients most likely to respond are strategic decisions that can define the success of your ADC program. Our integrated biomarker and tissue analysis platforms provide you with translational evidence to support indication selection and patient stratification strategies.

- Tissue microarray and target prevalence profiling
- Multiplex immunohistochemistry (IHC), RNAscope and spatial profiling
- Flow cytometry and tissue-based ex vivo analyses

FOLLOW US



THE SCIENCE CRO

YOUR PARTNER OF CHOICE IN BRINGING THERAPEUTICS TO LIFE

Nuvisan is a full-service contract research organisation (CRO) and development and manufacturing organisation (CDMO) with state-of-the-art laboratories in Germany and France.

Our pharmaceutical, biotechnology, venture capital and non-profit clients partner with us because our high-quality end-to-end solutions and scientific expertise enable us to streamline and accelerate drug discovery and development – from ensuring target understanding to helping bring therapeutics to life.

Founded over 40 years ago by a team of pharma industry innovators, Nuvisan has established a reputation for expertise and professionalism.

Our team leaders have extensive experience in the biopharma industry, and our unique centres of excellence – for drug discovery in Berlin, formulation and GMP manufacturing in Sophia Antipolis, and our bioanalysis hub in Neu-Ulm – enable our experienced scientists to help guide and advance projects.

We know how to discover, develop and bring the next generation of medicines to market. At the same time, we are committed to flexibility, transparency and collaboration in our approach, working closely with you to adapt to your individual needs, minimise risks and help deliver your project.

Contact us

NUVISAN

Nuvisan
Muellerstrasse 178
13353 Berlin
Germany

hello@nuvisan.com
+49 731 9840-0

nuvisan.com